BioPharmX Corporation (BPMX) financial statements (2020 and earlier)

Company profile

Business Address 900 E. HAMILTON AVE. SUITE 100
CAMPBELL, CA 95008
State of Incorp. DE
Fiscal Year End January 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2020
1/31/2019
1/31/2018
1/31/2017
1/31/2016
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1387420
Cash and cash equivalents1387420
Receivables 00000 
Inventory, net of allowances, customer advances and progress billings  0000
Inventory  0000 
Other undisclosed current assets0000000
Total current assets:1387430
Noncurrent Assets
Property, plant and equipment0000000
Intangible assets, net (including goodwill), including:    000
Intangible assets, net (excluding goodwill)    00 
Other undisclosed intangible assets, net (including goodwill)      0
Restricted cash and investments    00 
Other noncurrent assets00 000 
Other undisclosed noncurrent assets1     (0)
Total noncurrent assets:1000000
Other undisclosed assets      0
TOTAL ASSETS:2487530
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2234210
Accounts payable111320 
Accrued liabilities112100 
Employee-related liabilities    00 
Other undisclosed accounts payable and accrued liabilities      0
Debt0     1,230
Due to related parties    000
Deferred revenue and credits  000
Other undisclosed current liabilities    00(1,230)
Total current liabilities:2234311
Noncurrent Liabilities
Long-term debt and lease obligation      1
Long-term debt, excluding current maturities      1
Liabilities, other than long-term debt0 00   
Other liabilities0      
Derivative instruments and hedges, liabilities  00   
Other undisclosed noncurrent liabilities10     
Total noncurrent liabilities:1000  1
Total liabilities:2234312
Stockholders' equity
Stockholders' equity attributable to parent, including:(0)1532(5)(1)
Preferred stock   2   
Common stock0000000
Additional paid in capital888066462840
Accumulated deficit(88)(79)(61)(45)(26)(9) 
Other undisclosed stockholders' equity attributable to parent      (2)
Other undisclosed stockholders' equity     7 
Total stockholders' equity:(0)15322(1)
TOTAL LIABILITIES AND EQUITY:2487530

Income statement (P&L) ($ in millions)

1/31/2020
1/31/2019
1/31/2018
1/31/2017
1/31/2016
12/31/2014
12/31/2013
Revenues 0000  
Revenue, net000  
Cost of revenue
(Cost of Goods and Services Sold)
 (0)(0)(1)(0)  
Gross profit: (0)(0)(0)(0)  
Operating expenses(10)(16)(17)(18)(15)(8)(2)
Operating loss:(10)(17)(17)(18)(15)(8)(2)
Nonoperating income (expense)(0)(1)(0)(0)(0)0 
Debt instrument, convertible, beneficial conversion feature     0 
Other nonoperating income (expense)(0)(1)(0)(0)(0)0 
Interest and debt expense   (0) (0)(0)
Loss from continuing operations before equity method investments, income taxes:(10)(17)(17)(19)(16)(8)(2)
Other undisclosed income from continuing operations before income taxes0000   
Loss from continuing operations before income taxes:(10)(17)(17)(18)(16)(8)(2)
Income tax expense(0)(0)(0)(0)(0)  
Loss before gain (loss) on sale of properties:(10)(17)(17)(18)(16)(8)(2)
Other undisclosed net income      0
Net loss:(10)(17)(17)(18)(16)(8)(2)
Other undisclosed net loss attributable to parent     (0)(0)
Net loss attributable to parent:(10)(17)(17)(18)(16)(8)(2)
Preferred stock dividends and other adjustments    (0)(0) 
Other undisclosed net loss available to common stockholders, basic   (0)   
Net loss available to common stockholders, diluted:(10)(17)(17)(19)(16)(8)(2)

Comprehensive Income ($ in millions)

1/31/2020
1/31/2019
1/31/2018
1/31/2017
1/31/2016
12/31/2014
12/31/2013
Net loss:(10)(17)(17)(18)(16)(8)(2)
Comprehensive loss, net of tax, attributable to parent:(10)(17)(17)(18)(16)(8)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: